Take Homes from SABCS: Targeted Therapies

Take Homes from SABCS: Targeted Therapies

Source:

Sestak I, et al. Abstract GS2-02. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.

Disclosures: Moore reports no relevant financial disclosures.
December 14, 2020
1 min watch
Save

VIDEO: Preventing invasive, recurrent breast cancer in postmenopausal patients

Source:

Sestak I, et al. Abstract GS2-02. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.

Disclosures: Moore reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Halle Moore, MD, discussed preventive breast cancer treatments for patients who are postmenopausal and have locally excised ductal carcinoma in-situ.

The data analysis, which was presented at SABCS 2020, demonstrated similar efficacy between anastrozole and tamoxifen, but different side effect profiles, according to Moore, director of Breast Medical Oncology in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute.

“We really do have options for risk reduction in patients with ductal carcinoma in-situ,” she said. “We really should be choosing mostly based on toxicity profiles rather than efficacy of the different choices.”